Citadel Advisors’s VectivBio Holding AG Ordinary Shares VECT Stock Holding History

Citadel Advisors’s Portfolio VECT Stock Details VECT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,306	Closed	-$22K	–	15624
2023 Q2	$22K	Sell	1,306 -3,966,231	-100%	-$52.1M	﹤0.01%	12643
2023 Q1	$34.1M	Sell	3,967,537 -298	-0%	-$2.46K	0.01%	1422
2022 Q4	$34.2M	Buy	3,967,835 +822,584	+26%	+$6.62M	0.01%	1434
2022 Q3	$18.9M	Buy	3,145,251 +2,014	+0.1%	+$10.9K	﹤0.01%	1935
2022 Q2	$17M	Buy	3,143,237 +420,591	+15%	+$2.26M	﹤0.01%	2024
2022 Q1	$12.8M	Buy	2,722,646 +1,830	+0.1%	+$9.6K	﹤0.01%	2581
2021 Q4	$13.4M	Sell	2,720,816 -547	-0%	-$2.7K	﹤0.01%	2586
2021 Q3	$20.7M	Sell	2,721,363 -4,404	-0.2%	-$37.7K	﹤0.01%	1950
2021 Q2	$31.2M	Buy	+2,725,767	New	+$41.4M	0.01%	1568

Other funds holding VECT

Regency Capital Management Honolulu, Hawaii $251M AUM 32.13% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Citadel Advisors's VECT Position: Q3 2023 in Review

Citadel Advisors sold out of VectivBio Holding AG Ordinary Shares (VECT) in Q3 2023, closing a stake of 1,306 shares — an estimated $22K sold.

Citadel Advisors first reported a position in VECT in Q2 2021 and held it in 9 quarters. The position peaked at $34.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold VECT as of Q3 2023.

Citadel Advisors reported no remaining VectivBio Holding AG Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 1,306 VectivBio Holding AG Ordinary Shares shares in Q3 2023, an estimated $22K.
Citadel Advisors first reported a position in VectivBio Holding AG Ordinary Shares in Q2 2021 and held it in 9 quarters.
Citadel Advisors's VectivBio Holding AG Ordinary Shares position peaked at $34.2M in Q4 2022.
2 funds tracked by Wall St. Rank held VectivBio Holding AG Ordinary Shares as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.